WEX:NYSEWEX Inc. Analysis
Data as of 2026-05-10 - not real-time
$141.64
Latest Price
7/10Risk
Risk Level: Medium
Executive Summary
WEX posted a 5.8% year‑over‑year revenue increase to $673.8 million in Q1 2026 and delivered non‑GAAP EPS of $4.15, slightly beating consensus, while its full‑year revenue guidance of $2.85 billion sits 1.5% above analysts’ estimates. Operating margins remain robust at 23.5% and gross margins above 72%, supporting a strong cash conversion profile with free cash flow exceeding $1.2 billion. However, the stock slid 16% after the earnings release, and technical indicators are mixed: the MACD is bearish, the RSI sits at 36 (near oversold), and volume is trending down, suggesting short‑term pressure. The current price of $141.64 is far below the DCF‑derived fair value of $623, implying an upside potential of roughly 28% and an analyst consensus “Buy” rating with a median target near $176. With a beta around 1.0 and 30‑day volatility over 60%, the equity carries heightened market risk, but its high ROE (~30%) and strong balance sheet (cash > $5.4 billion, debt‑to‑equity > 400% driven by leveraged growth) provide a solid foundation for a rebound. The support level at $138 and resistance near $187 frame the near‑term trading range, while the extreme‑greed market sentiment (FGI 90.7) adds a bullish backdrop. Overall, the fundamentals are compelling, yet the near‑term technical weakness and liquidity concerns temper immediate enthusiasm.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Bearish MACD and decreasing volume indicate near‑term downside pressure
- Price is near support at $138, limiting downside risk
- Recent 16% earnings‑driven sell‑off creates a potential entry point
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- Fundamentals show strong revenue growth and high profitability margins
- DCF fair value suggests ~28% upside and analyst median target around $176
- Robust cash generation and low dividend reliance support reinvestment
Long Term
> 3 yearsPositive
Model confidence: 9/10
Key Factors
- Sustained high ROE and expanding SaaS platform across payments and benefits
- Strategic partnerships (e.g., Impactive Capital) broaden addressable market
- Long‑term valuation gap and industry positioning in high‑growth fintech infrastructure
Key Metrics & Analysis
Financial Health
Revenue Growth5.80%
Profit Margin11.50%
P/E Ratio16.0
ROE29.77%
ROA2.87%
Debt/Equity410.95
P/B Ratio3.9
Op. Cash Flow$605.1M
Free Cash Flow$1.3B
Industry P/E38.4
Technical Analysis
TrendNeutral
RSI36.4
Support$137.96
Resistance$186.86
MA 20$159.41
MA 50$157.88
MA 200$158.01
MACDBearish
VolumeDecreasing
Fear & Greed Index90.73
Valuation
Fair Value$623.27
Target Price$181.20
Upside/Downside27.93%
GradeUndervalued
TypeGrowth
Risk Assessment
Beta1.07
Volatility64.36%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.